Personal clinical trial finder

The information presented in the Myeloma Canada Personalized Clinical Trials Search Tool is from the International Clinical Trials database at ClinicalTrials.gov, indexed by the U.S. National Library of Medicine. Although the menu is in French, the details of the studies are only available in English.

Princess Margaret Cancer Centre clinical trials

Your search criteria - 52 result(s)

Print this list

POSTED : 2008-12-01 | START DATE : 2008-11-27 | LAST UPDATE : 2015-07-23

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

The Ottawa Hospital, Ottawa, Ontario – Recruiting

POSTED : 2009-05-12 | START DATE : 2009-05-09 | LAST UPDATE : 2024-05-02

Collection of Tissue Samples for Cancer Research

Condition: Multiple MyelomaMyelodysplastic Syndromes

Study phase:

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Hospital Cancer Centre, Toronto, – Completed

POSTED : 2012-08-15 | START DATE : 2012-08-13 | LAST UPDATE : 2023-04-26

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

University Health Network - Princess Margaret Cancer Center, Toronto, Ontario – Active, not recruiting

POSTED : 2013-04-24 | START DATE : 2013-04-19 | LAST UPDATE : 2023-02-16

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase:

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0065, Toronto, Ontario – Withdrawn

Local Institute, Toronto, Ontario – Recruiting

Local Institution - 0066, Toronto, Ontario – Completed

Other Centres

Local Institute, Weston, Ontario – Recruiting

POSTED : 2017-09-07 | START DATE : 2017-09-05 | LAST UPDATE : 2024-04-03

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

University of Calgary, Calgary, Alberta – Recruiting

Princess Margaret Cancer Center, Toronto, Ontario – Recruiting

Jewish General Hospital, Montreal, Quebec – Recruiting

POSTED : 2017-09-29 | START DATE : 2017-09-27 | LAST UPDATE : 2024-04-26

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Condition: Multiple MyelomaLymphoma, Non-Hodgkin

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia – Suspended

BCCA - Vancouver Cancer Centre, Vancouver, British Columbia – Recruiting

Other Centres

Kingston Health Sciences Centre, Kingston, Ontario – Recruiting

London Regional Cancer Program, London, Ontario – Recruiting

Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting

University Health Network, Toronto, Ontario – Recruiting

The Jewish General Hospital, Montreal, Quebec – Recruiting

Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

POSTED : 2018-10-11 | START DATE : 2018-09-25 | LAST UPDATE : 2023-12-05

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Condition: MeningiomaColorectal Neoplasms, Hereditary NonpolyposisUterine NeoplasmsHamartoma Syndrome, MultipleSyndrome

Study phase:

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2018-10-23 | START DATE : 2018-10-02 | LAST UPDATE : 2023-08-14

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

Vancouver General Hospital, Vancouver, British Columbia – Recruiting

CancerCare Manitoba, Winnipeg, Manitoba – Recruiting

Other Centres

QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting

Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

London Health Sciences Centre, London, Ontario – Recruiting

The Ottawa Hospital, Ottawa, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

POSTED : 2019-06-18 | START DATE : 2019-06-14 | LAST UPDATE : 2024-01-08

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Local Institution - 201, Calgary, Alberta – Recruiting

Local Institution - 205, Edmonton, Alberta – Recruiting

Local Institution - 204, Halifax, Nova Scotia – Recruiting

Other Centres

Local Institution - 203, Toronto, Ontario – Recruiting

Local Institution - 202, Montreal, Quebec – Recruiting

POSTED : 2019-07-18 | START DATE : 2019-04-24 | LAST UPDATE : 2020-03-27

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

Condition: Hematologic Neoplasms

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

London Health Sciences Centre-Victoria Hospital, London, Ontario – Recruiting

POSTED : 2019-08-28 | START DATE : 2019-08-07 | LAST UPDATE : 2023-08-11

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

BCCA-Vancouver Cancer Centre, Vancouver, British Columbia – Suspended

Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John, New Brunswick – Suspended

Kingston Health Sciences Centre, Kingston, Ontario – Suspended

Other Centres

Lakeridge Health Oshawa, Oshawa, Ontario – Suspended

POSTED : 2019-09-16 | START DATE : 2019-09-13 | LAST UPDATE : 2022-07-22

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

GSK Investigational Site, Edmonton, Alberta – Recruiting

GSK Investigational Site, London, Ontario – Completed

POSTED : 2019-10-15 | START DATE : 2019-10-11 | LAST UPDATE : 2024-02-23

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

GSK Investigational Site, Edmonton, Alberta – Recruiting

GSK Investigational Site, Vancouver, British Columbia – Recruiting

GSK Investigational Site, Halifax, Nova Scotia – Recruiting

Other Centres

GSK Investigational Site, Toronto, Ontario – Recruiting

POSTED : 2020-02-13 | START DATE : 2020-02-10 | LAST UPDATE : 2023-10-12

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

POSTED : 2020-07-23 | START DATE : 2020-07-21 | LAST UPDATE : 2023-10-31

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

GSK Investigational Site, Ottawa, Ontario – Recruiting

GSK Investigational Site, Toronto, Ontario – Recruiting

GSK Investigational Site, Montreal, – Recruiting

POSTED : 2020-10-14 | START DATE : 2020-10-12 | LAST UPDATE : 2024-04-23

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

Alberta Health Services, Edmonton, Alberta – Recruiting

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting

Other Centres

McGill University Health Centre, Montreal, Quebec – Recruiting

POSTED : 2021-06-02 | START DATE : 2021-05-27 | LAST UPDATE : 2024-04-25

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Hamilton Health Sciences, Hamilton, Ontario – Recruiting

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario – Recruiting

POSTED : 2021-06-11 | START DATE : 2021-06-10 | LAST UPDATE : 2024-04-23

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Active, not recruiting

Vancouver General Hospital, Vancouver, British Columbia – Active, not recruiting

Juravinski Cancer Centre, Hamilton, Ontario – Active, not recruiting

Other Centres

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Active, not recruiting

Hopital Maisonneuve-Rosemont, Montréal, Quebec – Active, not recruiting

POSTED : 2021-07-22 | START DATE : 2021-07-07 | LAST UPDATE : 2024-04-24

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Other Centres

Jewish General Hospital, Montreal, Quebec – Recruiting

POSTED : 2021-07-26 | START DATE : 2021-07-02 | LAST UPDATE : 2024-05-02

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Local Institution - 111, Calgary, Alberta – Completed

Local Institution - 103, Edmonton, Alberta – Completed

BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia – Recruiting

Other Centres

Local Institution - 104, Saint John, New Brunswick – Completed

Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador – Recruiting

Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia – Recruiting

Local Institution - 109, Ottawa, Quebec – Completed

Local Institution - 107, Saskatoon, Saskatchewan – Completed

CHU de Quebec-Universite Laval, Quebec, – Recruiting

POSTED : 2021-08-25 | START DATE : 2021-08-11 | LAST UPDATE : 2024-03-08

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Active, not recruiting

Cross Cancer Institute, Edmonton, Alberta – Active, not recruiting

QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Active, not recruiting

Other Centres

Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia – Active, not recruiting

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Active, not recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Active, not recruiting

Jewish General Hospital, Montreal, Quebec – Active, not recruiting

CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, Quebec – Active, not recruiting

Saskatoon Cancer Center, Saskatoon, Saskatchewan – Active, not recruiting

POSTED : 2021-10-01 | START DATE : 2021-09-22 | LAST UPDATE : 2023-04-10

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

GSK Investigational Site, Oshawa, Ontario – Recruiting

GSK Investigational Site, Toronto, Ontario – Recruiting

GSK Investigational Site, Montreal, Quebec – Recruiting

Other Centres

GSK Investigational Site, Montréal, Quebec – Recruiting

POSTED : 2021-10-25 | START DATE : 2021-10-08 | LAST UPDATE : 2024-04-11

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2021-12-29 | START DATE : 2021-12-22 | LAST UPDATE : 2024-05-02

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Novartis Investigative Site, Calgary, Alberta – Active, not recruiting

POSTED : 2022-01-13 | START DATE : 2021-12-07 | LAST UPDATE : 2023-02-28

Early Integration of Palliative and Supportive Care in Cellular Therapy

Condition: Multiple MyelomaHematologic Neoplasms

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

POSTED : 2022-02-07 | START DATE : 2022-02-02 | LAST UPDATE : 2023-09-19

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario – Recruiting

POSTED : 2022-02-25 | START DATE : 2022-02-16 | LAST UPDATE : 2024-03-05

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, – Not yet recruiting

Cross Cancer Institute, Edmonton, – Not yet recruiting

McMaster University, Hamilton, – Not yet recruiting

Other Centres

Hopital Maisonneuve-Rosemont, Montréal, – Not yet recruiting

Mcgill University Health Centre, Montréal, – Not yet recruiting

Ottawa Hospital Research Institute, Ottawa, – Not yet recruiting

(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, – Not yet recruiting

Princess Margaret Cancer Centre, Toronto, – Not yet recruiting

Vancouver General Hospital, Vancouver, – Not yet recruiting

POSTED : 2022-04-07 | START DATE : 2022-03-18 | LAST UPDATE : 2024-04-29

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting

Saint John Regional Hospital, Saint John, New Brunswick – Recruiting

Other Centres

Hamilton Health Sciences Corporation, Hamilton, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Windsor Regional Hospital Cancer Program, Windsor, Ontario – Not yet recruiting

Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal,, Montreal, Quebec – Recruiting

McGill University Health Centre, Montreal, Quebec – Recruiting

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSS, Montreal, Quebec – Recruiting

POSTED : 2022-05-12 | START DATE : 2022-05-06 | LAST UPDATE : 2024-02-26

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta – Recruiting

University of Alberta - Cross Cancer Institute, Edmonton, Alberta – Recruiting

University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario – Recruiting

POSTED : 2022-06-06 | START DATE : 2022-05-31 | LAST UPDATE : 2024-03-05

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Investigational Site Number : 1240001, Toronto, Ontario – Recruiting

Investigational Site Number : 1240004, Greenfield Park, Quebec – Recruiting

Investigational Site Number : 1240003, Montreal, Quebec – Recruiting

POSTED : 2022-08-29 | START DATE : 2022-08-25 | LAST UPDATE : 2024-05-02

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, Quebec – Recruiting

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎM) - Hôpital du Sacré-Coeur, Montreal, Quebec – Recruiting

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Quebec City, Quebec – Recruiting

POSTED : 2022-09-23 | START DATE : 2022-09-21 | LAST UPDATE : 2024-05-01

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting

Victoria Hospital & Children's Hospital - London Health Sciences Centre, London, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Other Centres

Local Institution - 0186, Montreal, Quebec – Withdrawn

POSTED : 2022-10-07 | START DATE : 2022-10-05 | LAST UPDATE : 2024-04-23

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

Saint John Regional Hospital, Saint John, New Brunswick – Recruiting

Brampton Civic Hospital, Brampton, Ontario – Recruiting

Other Centres

Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting

CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – Recruiting

POSTED : 2022-11-21 | START DATE : 2022-10-26 | LAST UPDATE : 2024-04-15

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2022-12-09 | START DATE : 2022-11-30 | LAST UPDATE : 2024-04-12

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

Condition: Multiple Myeloma

Study phase:

Recruitment status: Recruiting

Nearest centres:

Edith Pituskin, Edmonton, Alberta – Recruiting

POSTED : 2022-12-14 | START DATE : 2022-12-06 | LAST UPDATE : 2024-02-02

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Juravinski Cancer Centre /ID# 252053, Hamilton, Ontario – Recruiting

Ottawa Hospital Research Institute /ID# 252151, Ottawa, Ontario – Recruiting

POSTED : 2022-12-15 | START DATE : 2022-12-01 | LAST UPDATE : 2023-10-23

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario – Recruiting

POSTED : 2023-02-15 | START DATE : 2023-02-06 | LAST UPDATE : 2024-04-29

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

The Ottawa Hospital, Ottawa, Ontario – Recruiting

University Health Network (UHN) - Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2023-04-24 | START DATE : 2023-04-11 | LAST UPDATE : 2024-04-09

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting

Local Institution - 0307, Montreal, Quebec – Not yet recruiting

Other Centres

CHUQ - The Hôtel-Dieu de Québec, Quebec, – Recruiting

POSTED : 2023-09-21 | START DATE : 2023-09-13 | LAST UPDATE : 2024-04-09

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0133, Edmonton, Alberta – Not yet recruiting

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

Local Institution - 0134, Montreal, Quebec – Not yet recruiting

POSTED : 2023-09-26 | START DATE : 2023-09-20 | LAST UPDATE : 2024-04-12

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Hamilton Health Sciences, Hamilton, Ontario – Recruiting

POSTED : 2023-09-28 | START DATE : 2023-09-05 | LAST UPDATE : 2024-02-14

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 4

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

Cross Cancer Institute, Edmonton, Alberta – Recruiting

McGill University Health Centre, Montréal, Quebec – Recruiting

POSTED : 2023-10-30 | START DATE : 2023-10-11 | LAST UPDATE : 2024-04-29

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Research Site, Hamilton, Ontario – Not yet recruiting

Research Site, Montreal, Quebec – Not yet recruiting

POSTED : 2023-11-30 | START DATE : 2023-11-17 | LAST UPDATE : 2024-04-29

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Jewish General Hospital, Montreal, Quebec – Not yet recruiting

POSTED : 2023-12-27 | START DATE : 2023-12-13 | LAST UPDATE : 2024-04-11

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario – Recruiting

POSTED : 2024-01-17 | START DATE : 2024-01-05 | LAST UPDATE : 2024-04-23

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – Recruiting

POSTED : 2024-01-22 | START DATE : 2024-01-10 | LAST UPDATE : 2024-04-12

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting

POSTED : 2024-01-25 | START DATE : 2023-12-27 | LAST UPDATE : 2024-02-07

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Condition: LymphomaMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseWaldenstrom Macroglobulinemia

Study phase:

Recruitment status: Not yet recruiting

Nearest centres:

BC Cancer, Vancouver, British Columbia – ()

POSTED : 2024-01-31 | START DATE : 2024-01-22 | LAST UPDATE : 2024-03-27

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Not yet recruiting

Nearest centres:

Local Institution - 0417, Calgary, Alberta – ()

Local Institution - 0423, Edmonton, Alberta – ()

Local Institution - 0402, London, Ontario – ()

Other Centres

Local Institution - 0395, Toronto, Ontario – ()

Local Institution - 0031, Montreal, Quebec – ()

Local Institution - 0098, Montréal, Quebec – ()

POSTED : 2024-02-28 | START DATE : 2024-02-19 | LAST UPDATE : 2024-02-19

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: N/A

Recruitment status: Not yet recruiting

Nearest centres:

University of Alberta/ Cross Cancer Institute, Edmonton, Alberta – ()

POSTED : 2024-03-07 | START DATE : 2024-02-28 | LAST UPDATE : 2024-03-27

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0020, Calgary, Alberta – Not yet recruiting

Local Institution - 0021, Montréal, Quebec – Not yet recruiting

POSTED : 2024-05-03 | START DATE : 2024-05-01 | LAST UPDATE : 2024-05-01

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0133, Edmonton, Alberta – Not yet recruiting

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

Local Institution - 0134, Montreal, Quebec – Not yet recruiting